In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|June 14, 2017
Irvine Scientific Adds R&D Center in CA
Author(s)BioPharm International Editors
The company added a 40,000-ft2 purpose-built R&D center at 17112 Armstrong Ave, Irvine, CA.
Advertisement
On June 13, 2017, Irvine Scientific announced the expansion of its Orange County, CA offices and laboratories, with the addition of a 40,000-ft2 purpose-built R&D center at 17112 Armstrong Ave, Irvine, CA. According to the company, this follows the significant expansion of its R&D facilities less than five years ago.
The new building will also contain other departments that currently reside within its southern CA headquarters enabling the company to expand other capabilities, such as media customization for customers, conducted at its headquarters in Santa Ana. Along with the other facilities in Santa Ana, CA, this increases the total space occupied by Irvine Scientific in Orange County to more than 140,000 ft2.
With the opening of the new facility, Irvine Scientific plans to expand the laboratories and staff located in its main headquarters. As the company continues to grow, it intends to continue to expand its offering of products and services to biopharmaceutical, stem and immune cell therapy companies, and medical devices for the IVF laboratories worldwide.
Source: Irvine Scientific
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5